Literature DB >> 20875693

Community views on neurologic emergency treatment trials.

Scott E Kasner1, Jill M Baren, Peter D Le Roux, Pamela G Nathanson, Katherine Lamond, Stacy L Rosenberg, Jason Karlawish.   

Abstract

STUDY
OBJECTIVE: We improve our understanding of the community consultation process for acute neurologic emergency trials conducted under the federal regulations for Exception From Informed Consent (EFIC) for emergency research.
METHODS: We performed a qualitative study using focus groups to collect data from patients with a previous stroke or brain injury and their families and from young men at risk for traumatic brain injury. Discussions were transcribed, coded, and analyzed for major themes and subthemes.
RESULTS: Five focus groups, involving 40 participants, were convened. Major themes included the awareness and understanding of key clinical trial concepts, including prominent concerns about placebo and therapeutic misconception; inability to obtain informed consent and acceptable surrogate decision-making; EFIC in emergency research and whether existing regulations are acceptable; specific trial design problems, including comparison to standard of care versus 2 competing active therapies; and community consultation and representation.
CONCLUSION: In this study sample, EFIC trials were deemed appropriate and acceptable for acute neurologic emergency research. Education, along with open discussion about basic clinical research concepts, disease- and trial-specific information, and potential surrogate decision-making, was essential to determine the acceptability of an EFIC trial. Approval by institutional review boards was highly regarded as a means of human protection and effective community consultation for such trials. A data repository of information gained from similar qualitative research may help investigators and regulators who wish to plan, conduct, review, and provide oversight for acute neurologic emergency trials under EFIC regulations.
Copyright © 2010 American College of Emergency Physicians. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20875693     DOI: 10.1016/j.annemergmed.2010.07.009

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  17 in total

1.  Variation of community consultation and public disclosure for a pediatric multi-centered "Exception from Informed Consent" trial.

Authors:  Maija Holsti; Roger Zemek; Jill Baren; Rachel M Stanley; Prashant Mahajan; Cheryl Vance; Kathleen M Brown; Victor Gonzalez; Denise King; Kammy Jacobsen; Kate Shreve; Katrina van de Bruinhorst; Anne Marie Jones; James M Chamberlain
Journal:  Clin Trials       Date:  2014-11-04       Impact factor: 2.486

2.  Incentives and barriers to neurological clinical research participation.

Authors:  Anne S Lindblad; Pam Zingeser; Nil Sismanyazici-Navaie
Journal:  Clin Investig (Lond)       Date:  2011-12

3.  Impact of individual clinical outcomes on trial participants' perspectives on enrollment in emergency research without consent.

Authors:  Louisa W Whitesides; Jill M Baren; Michelle H Biros; Ross J Fleischman; Prasanthi R Govindarajan; Elizabeth B Jones; Arthur M Pancioli; Rebecca D Pentz; Victoria M Scicluna; David W Wright; Neal W Dickert
Journal:  Clin Trials       Date:  2016-11-15       Impact factor: 2.486

4.  Public Deliberation as a Novel Method for an Exception From Informed Consent Community Consultation.

Authors:  Patricia E Powers; Karen K Shore; Susan Perez; Dominique Ritley; Nathan Kuppermann; James F Holmes; Leah S Tzimenatos; Hiwote Shawargga; Daniel K Nishijima
Journal:  Acad Emerg Med       Date:  2019-07-24       Impact factor: 3.451

5.  Patients' perspectives of enrollment in research without consent: the patients' experiences in emergency research-progesterone for the treatment of traumatic brain injury study.

Authors:  Neal W Dickert; Victoria M Scicluna; Jill M Baren; Michelle H Biros; Ross J Fleischman; Prasanthi R Govindarajan; Elizabeth B Jones; Arthur M Pancioli; David W Wright; Rebecca D Pentz
Journal:  Crit Care Med       Date:  2015-03       Impact factor: 7.598

6.  Stroke treatment academic industry roundtable: research priorities in the assessment of neurothrombectomy devices.

Authors:  Jeffrey L Saver; Tudor G Jovin; Wade S Smith; Gregory W Albers; Jean-Claude Baron; Johannes Boltze; Joseph P Broderick; Lisa A Davis; Andrew M Demchuk; Salvatore DeSena; Jens Fiehler; Philip B Gorelick; Werner Hacke; Bill Holt; Reza Jahan; Hui Jing; Pooja Khatri; Chelsea S Kidwell; Kennedy R Lees; Michael H Lev; David S Liebeskind; Marie Luby; Patrick Lyden; J Thomas Megerian; J Mocco; Keith W Muir; Howard A Rowley; Richard M Ruedy; Sean I Savitz; Vitas J Sipelis; Samuel K Shimp; Lawrence R Wechsler; Max Wintermark; Ona Wu; Dileep R Yavagal; Albert J Yoo
Journal:  Stroke       Date:  2013-11-05       Impact factor: 7.914

7.  Enrollment in research under exception from informed consent: the Patients' Experiences in Emergency Research (PEER) study.

Authors:  Neal W Dickert; Victoria A Mah; Jill M Baren; Michelle H Biros; Prasanthi Govindarajan; Arthur Pancioli; Robert Silbergleit; David W Wright; Rebecca D Pentz
Journal:  Resuscitation       Date:  2013-04-16       Impact factor: 5.262

8.  Consulting communities when patients cannot consent: a multicenter study of community consultation for research in emergency settings.

Authors:  Neal W Dickert; Victoria A Mah; Michelle H Biros; Deneil M Harney; Robert Silbergleit; Jeremy Sugarman; Emir Veledar; Kevin P Weinfurt; David W Wright; Rebecca D Pentz
Journal:  Crit Care Med       Date:  2014-02       Impact factor: 7.598

9.  Informed consent: the rate-limiting step in acute stroke trials.

Authors:  David Z Rose; Scott E Kasner
Journal:  Front Neurol       Date:  2011-10-17       Impact factor: 4.003

10.  Willingness to participate in clinical trials among patients of Chinese heritage: a meta-synthesis.

Authors:  Alexander Limkakeng; Amruta Phadtare; Jatin Shah; Meenakshi Vaghasia; Ding Ying Wei; Anand Shah; Ricardo Pietrobon
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.